ArticlePediatric radiology2025
Integrating neuron-specific enolase and venous-phase enhanced computed tomography radiomics for improved survival prediction in high-risk neuroblastoma: a two-center study.
Article in Pediatric radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHigh-risk neuroblastoma is associated with a poor prognosis, making it crucial to identify patients within this group who face an even higher risk of adverse outcomes.
objectiveTo determine if integrating clinical indicators and venous-phase enhanced computed tomography radiomics features could improve the prediction of overall survival in high-risk neuroblastoma. MATERIALS AND
methodsWe retrospectively included high-risk neuroblastoma patients treated at a primary institution, randomly stratifying them into a training set (70%) and a test set (30%). Univariate and multivariate Cox regression analyses were used to identify independent clinical risk factors. We then extracted radiomics features from venous-phase enhanced computed tomography images. Clinical risk factors, radiomics score, and combined model were evaluated in the training, test, and external validation sets.
resultsThe training, test, and validation sets included 70, 30, and 40 patients, respectively. Neuron-specific enolase was identified as the independent clinical risk factor, with concordance indices of 0.616, 0.627, and 0.595 in the training, test, and validation sets, respectively. The radiomics score achieved concordance indices of 0.699, 0.690, and 0.684 in the training, test, and validation sets, respectively. The combined model showed concordance indices of 0.730, 0.707, and 0.690 in the training, test, and validation sets, respectively. The combined model predicted 5-year overall survival with an area under the receiver operating characteristic curve of 0.780 in the training set, 0.742 in the test set, and 0.710 in the validation set.
conclusionCombining neuron-specific enolase and venous-phase enhanced computed tomography radiomics improves survival prediction in high-risk neuroblastoma.
Indexed as
Identifiers
40327094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.